Alere (ALR) volatility flat into Abbott Laboratories (ABT) agreeing to buy at $51 per share rather than previous offer of $56
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Alere (ALR) PT Lowered to $51 at Canaccord Genuity
April 17, 2017 9:27 AM EDTCanaccord Genuity lowered its price target on Alere (NYSE: ALR) to $51.00 (from $52.00) while maintaining a Buy rating. ABT and ALR announced a settlement at $51/share, or ~21% higher than ALR's closing price of $42.31 last Thursday.
Canaccord believes that shareholders would have approved anything at $50+ so... More
Alere (ALR) PT Lowered to $51 at Jefferies Following Announced Revisions to ABT Merger
April 17, 2017 7:17 AM EDTJefferies lowered its price target on Alere (NYSE: ALR) to $51.00 (from $56.00) while maintaining a Hold rating following the company's announced amended the terms of to the merger with ABT.
Key revisions include: 1) $51/share vs. the original $56; 2) timeline extended to September 30 from April 30; and... More

